The NYSE Welcomes vVARDIS as a Publicly Listed Company

(Low)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

The New York Stock Exchange welcomed vVARDIS (NYSE: VVVV) as a publicly listed Swiss dental technology company.

Founded by Dr. Haley Abivardi and Dr. Goly Abivardi, vVARDIS focuses on treating early tooth decay. Its flagship product, Curodont Repair Fluoride Plus, uses peptide technology to support enamel remineralization. The company says the technology has treated more than 2.5 million teeth and is available in more than 20% of U.S. dental practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/13/2026 - 05:56 PM EST

NEW YORK, Nov. 13, 2026 /PRNewswire/ -- vVARDIS (NYSE: VVVV) co-founders Dr. Haley Abivardi and Dr. Goly Abivardi aim to reshape the future of dental care with a drill-free treatment for the world's #1 non-communicable disease: cavities.

vVARDIS Solves a Problem that Millions Face
- Tooth decay affects billions of people worldwide, and dental anxiety keeps millions from getting the care they need.
- vVARDIS is a Swiss dental technology company focused on changing the way early tooth decay is treated.
- vVARDIS has introduced a new approach that aims to treat decay earlier and more comfortably for patients.
- Its flagship product, Curodont^® Repair Fluoride Plus, uses proprietary peptide technology to help repair early-stage tooth decay by supporting the natural remineralization of enamel --- simply put No drill, No needle, or No filling.
Tooth Decay is One of the Most Common Health Issues in the World
- 2.5 billion people globally live with untreated tooth decay.
- Nearly 90% of U.S. adults have experienced tooth decay.
- Nearly 73% of U.S. adults report dental fear.
- 21% avoid the dentist because of anxiety.
The Story that Helped Shape vVARDIS
- For decades, treating early tooth decay often meant waiting until it worsened or getting a filling.
- The founders spent 25 years developing Curodont^® Repair Fluoride Plus, a treatment that helps repair early tooth decay before it becomes a cavity.
- Curodont^® gives dentists a way to treat early decay while making the experience easier and less intimidating for patients.
  - The technology has already treated more than 2.5 million teeth
  - Available in more than 20% of U.S. dental practices